Last updated Jun 6, 2026
Jiangsu Hansoh Pharma
Evidence Sources
5
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
1
Confidence Coverage
77%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Diabetes
- SGLT2 Inhibitor
Highest priority development: Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor Competition
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 77%
Active Signals
1
Investigate Priority
0
Opportunity Score
24
Buyer Quality
3 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 24FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma
Diabetes · SGLT2 Inhibitor
Related Assets
Portfolio asset pages with evidence-based assessments.
- Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor CompetitionModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — DAPAGLIFLOZIN (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — DAPAGLIFLOZIN (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — DAPAGLIFLOZIN (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor CompetitionModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Jiangsu Hansoh Pharma right now?
- Which regulatory precedents should Jiangsu Hansoh Pharma monitor in Diabetes and SGLT2 Inhibitor?
- How does Jiangsu Hansoh's Dapagliflozin Submission Intensifies SGLT2 Inhibitor Competition compare to the nearest competitive programs?
- What signals require immediate investigation for Jiangsu Hansoh Pharma?
- Summarize the strategic implications of recent developments for Jiangsu Hansoh Pharma.
- Where is the greatest uncertainty in Jiangsu Hansoh Pharma's competitive positioning?